SCHEMBL16183934

SCHEMBL16183934

Clc1cccc(-c2ccc3nc(-c4cccnc4)nc(NCc4ccccn4)c3c2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 12/20 0.66
▸ KCNA5 P22460 2/20 0.62
▸ KCNH2 Q12809 1/20 0.62
▸ MEN1 O00255 4/20 0.61
▸ KMT2A Q03164 4/20 0.61
▸ MAPT P10636 2/20 0.61
▸ GAA P10253 1/20 0.61
▸ GBA1 P04062 2/20 0.57
▸ CLK4 Q9HAZ1 3/20 0.56
▸ ALDH1A1 P00352 4/20 0.53
▸ CYP1A2 P05177 4/20 0.53
▸ CYP3A4 P08684 4/20 0.53
▸ HSD17B10 Q99714 4/20 0.53
▸ JAK2 O60674 1/20 0.53
▸ LCK P06239 1/20 0.53
▸ LYN P07948 1/20 0.53
▸ CDK2 P24941 1/20 0.53
▸ TYK2 P29597 1/20 0.53
▸ TXK P42681 1/20 0.53
▸ NR2C2 P49116 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16183935 0.93 PDE5A (0.67) PDE5AKCNA5KCNH2MEN1KMT2A
SCHEMBL16183937 0.92 MEN1 (0.61) PDE5AKCNA5KCNH2MEN1KMT2A
SCHEMBL16183924 0.92 PDE5A (0.77) PDE5AKCNA5KCNH2MEN1KMT2A
SCHEMBL16183711 0.92 KCNA5 (0.66) PDE5AKCNA5KCNH2MEN1KMT2A
SCHEMBL16183707 0.89 PDE5A (0.66) PDE5AKCNA5KCNH2MEN1KMT2A
SCHEMBL16183713 0.89 PDE5A (0.66) PDE5AKCNA5KCNH2MEN1KMT2A
SCHEMBL16183709 0.89 PDE5A (0.60) PDE5AKCNA5KCNH2MEN1KMT2A
SCHEMBL16183708 0.88 PDE5A (0.68) PDE5AKCNA5KCNH2MEN1KMT2A
SCHEMBL16183933 0.88 KCNA5 (0.64) PDE5AKCNA5KCNH2MEN1KMT2A
SCHEMBL16183714 0.87 PDE5A (0.67) PDE5AKCNA5KCNH2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB PDE5A 704/4885KCNA5 4457/4885KCNH2 4620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback